Role and inhibition of GLI1 protein in cancer

Authors :: Mario Milani
Eloise Mastrangelo
Source :: Lung Cancer: Targets and Therapy, Vol Volume 9, Pp 35-43 (2018), Lung cancer (Auckl.) 9 (2018): 35–43. doi:10.2147/LCTT.S124483, info:cnr-pdr/source/autori:Mastrangelo E, Milani M/titolo:Role and inhibition of GLI1 protein in cancer/doi:10.2147%2FLCTT.S124483/rivista:Lung cancer (Auckl.)/anno:2018/pagina_da:35/pagina_a:43/intervallo_pagine:35–43/volume:9, Lung Cancer: Targets and Therapy
Publication Year :: 2018
Publisher :: Dove Medical Press, 2018.
Abstract: Eloise Mastrangelo, Mario Milani CNR – Biophysics Institute, c/o Dipartimento di Bioscienze, Università degli Studi di Milano, Milano, Italy Abstract: GLI1 is a transcriptional regulator involved in the development of different types of cancer. GLI1 transcriptional activity is regulated within the Hedgehog pathway (canonical activity), but can also be controlled independently (non-canonical activity) in the context of other signaling pathways. Experimental evidences show GLI1 involvement in both small- and non–small-cell lung cancers. Direct inhibition of the protein, in combination with other chemotherapeutic agents, represents a promising strategy for the treatment of different malignancies. Keywords: Hedgehog pathway, transcriptional regulator, lung cancer, inhibitors